The present invention relates to methods of producing porcine circovirus (PCV) pseudovirions in plant cells, the plant-produced PCV pseudovirions, a neutralisation assay using the plant-produced PCV pseudovirions and pharmaceutical compositions comprising the plant produced PCV pseudovirions. In particular, the method of the invention relates to introducing expression vectors, replicating vectors and nucleic acids into the plant cell and allowing for expression of capsid proteins and replication of the replicating vector. The expressed PCV capsid polypeptides assemble, together with a single-stranded copy of the replicating vector and encapsidate it as a pseudogenome to produce a PCV pseudovirion.

Transport of a vaporizable liquid containing at least one solute through a material containing nanochannels is performed by contacting material with at least one vaporizable liquid component and inducing liquid transport along nanochannel interior wall surfaces, wherein the material contains nanochannels having an average diameter up to about 300 nm, preferably up to about 100 nm, and liquid transport is induced by partial liquid vaporization. A film of solid material is deposited onto an interior nanochannel wall surface by removing the transport liquid.

The present disclosure relates to a composition for detecting a potato virus Y including an M13KO7 bacteriophage and a kit including the same. Since the M13KO7 bacteriophage of the present disclosure may be easily produced using E. coli and is a large aggregate of proteins, the M13KO7 bacteriophage is more stable than antibodies even when exposed to external physical or chemical factors. Therefore, the composition of the present disclosure has an effect of diagnosing only the PVY specifically and accurately and may be usefully used in related industries.

The disclosure relates to methods and reagents for analyzing samples for the presence of JC virus antibodies. Disclosed is a method that includes obtaining a biological sample from a subject (e.g., plasma, serum, blood, urine, or cerebrospinal fluid), contacting the sample with highly purified viral-like particles (HPVLPs) under conditions suitable for binding of a JCV antibody in the sample to an HPVLP, and detecting the level of JCV antibody binding in the sample to HPVLP. In one embodiment, determining the level of anti-JCV antibodies in the subject sample provides a method of identifying PML risk in a subject.

The present invention is an antibody including an amino acid sequence, wherein the amino acid sequence includes, in an N- to C-direction, the following structural domains:
N-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4-C
wherein FR denotes a framework region amino acid sequence and CDR denotes a complementary determining region amino acid sequence; the CDR1 includes an amino acid sequence represented by SEQ ID NO: 1; the CDR2 includes an amino acid sequence represented by SEQ ID NO: 2; and the CDR3 includes an amino acid sequence represented by SEQ ID NO: 3. The antibody is capable of binding to an intranuclear protein of an influenza virus.

The invention relates to certain methods for the determination of an antigen content of a first antigen in a mixture comprising two or more antigens. The invention also relates to a potency test for an antigen in a combination vaccine. The method allows the determination of the antigen content in a mixture additionally comprising antibodies that are capable of binding with the antigen.

The present invention provides, inter alia, a device comprising a colorimetric detection layer configured to undergo a color change upon interaction with a first analyte of interest. The detection layer comprises a first plurality of self-assembled fiber bundles. At least a fraction of the fiber bundles undergo a change from a first conformation to a second conformation upon interaction with the first analyte of interest, thereby undergoing a color change. The invention also provides a method for using the system to detect an analyte of interest.

The invention provides methods and mass-labeled peptides for use in said methods for quantifying the presence of a one or more viral proteins in a sample of a preparation containing agents which bind to said viral protein, using mass-spectroscopic analyses of the sample and standards containing known amounts of labeled and unlabeled signature peptides, in particular wherein said viral proteins are antigens in a vaccine for porcine circovirus.

Provided herein, in some aspects, are methods of administering to a subject a thymidine kinase substrate having a label and detecting presence or absence of the label as an indication of the presence of a polyomavirus (e.g., JCV and BK).

A conductive channel-containing membrane includes a membrane layer, and a SPP1 connector polypeptide variant that is incorporated into the membrane layer to form an aperture through which conductance can occur when an electrical potential is applied across the membrane. A method of sensing a molecule, such as a polypeptide or nucleic acid molecule, makes use of the conductive channel-containing membrane. A method of DNA sequence makes use of the conductive channel-containing membrane.